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Abstract
Background: Central venous catheter (CVC)-related infections are a substantial problem in the intensive care unit
(ICU). Our infection control team initiated the routine use of antiseptic-coated (chlorhexidine–silver sulfadia-
zine; Chx-SS) CVCs in our adult ICUs to reduce catheter-associated (CA) and catheter-related (CR) blood stream
infection (BSI) as we implemented other educational and best practice standardization strategies. Prior ran-
domized studies documented that the use of Chx-SS catheters reduces microbial colonization of the catheter
compared with an uncoated standard (Std) CVC but does not reduce CR-BSI. We therefore implemented the
routine use of uncoated Std CVCs in our surgical ICU (SICU) and examined the impact of this change.
Hypothesis: The use of uncoated Std CVCs does not increase CR-BSI rate in an SICU.
Methods: Prospective evaluation of universal use of uncoated Std CVCs, implemented November 2007 in the
SICU. The incidences of CA-BSI and CR-BSI were compared during November 2006–October 2007 (universal
use of Chx-SS CVCs) and November 2007–October 2008 (universal use of Std CVCs) by t-test. The definitions of
the U.S. Centers for Disease Control and Prevention were used for CA-BSI and CR-BSI. Patient data were
collected via a dedicated Acute Physiology and Chronic Health Evaluation (APACHE) III coordinator for the
SICU.
Results: Annual use of CVCs increased significantly in the last six years, from 3,543 (2001) to 5,799 (2006) total
days. The APACHE III scores on day 1 increased from a mean of 54.4 in 2004 to 55.6 in 2008 (p¼ 0.0010; 95%
confidence interval [CI] 1.29-5.13). The mean age of the patients was unchanged over this period, ranging from
58.2 to 59.6 years. The Chx-SS catheters were implemented in the SICU in 2002. Data regarding the specific
incidence of CR-BSI were collected beginning at the end of 2005, with mandatory catheter tip cultures when
CVCs were removed. Little difference was identified in the incidence of BSI between the interval with universal
Chx-SS use and that with Std CVC use. (Total BSI 0.7 vs. 0.8 per 1,000 catheter days; CA-BSI 0.5 vs. 0.8 per 1,000
catheter days; CR-BSI 0.2 vs. 0 per 1,000 catheter days.) No difference was seen in the causative pathogens of CA-
BSI or CR-BSI.
Conclusion: Eliminating the universal use of Chx-SS-coated CVCs in an SICU with a low background incidence
of CR-BSIs did not result in an increase in the rate of CR-BSIs. This study documents the greater importance of
adherence to standardization of the processes of care related to CVC placement than of coated CVC use in the
reduction of CR-BSI.
Central venous catheters (CVCs) can be life-saving forthose who require central access for medications, fluids,
and nutrition, but their use is not without risk. In particular,
catheter-related (CR) infections are a significant source of
morbidity and death in hospitalized patients [1]. The U.S.
Centers for Disease Control and Prevention (CDC) estimates
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an annual occurrence of more than 250,000 CR-BSIs in the
United States alone [2]. In addition to the lives lost as a result
of CR blood stream infection (BSI), the estimated financial
impact of even one BSI can be substantial [3–6]. Because of
this, CR-BSIs have been deemed preventable and targeted for
eradication by influential medical bodies, including the CDC
[2], the Society for Healthcare Epidemiology of America
(SHEA) [6], the Infectious Diseases Society of America
(IDSA)[7, 8], the 100,000 Lives Campaign, and the 5 Million
Lives Campaign from the Institute for Healthcare Improve-
ment [9].
The CDC Guidelines for the Prevention of Intravascular
Catheter-Related Infections recommend preventive strategies
with strong supportive evidence, including: (1) Education and
training of healthcare providers; (2) use of full barrier pre-
cautions during CVC insertion; (3) use of a 2% chlorhexidine
preparation for skin antisepsis; (4) no routine replacement of
CVCs; and (5) use of an antiseptic/antibiotic-impregnated
CVC in adults whose catheter is expected to remain in place
longer than five days if, after implementing a comprehensive
strategy to reduce the rate of CR-BSI, the infection rate re-
mains above the goal set by the individual institution on the
basis of benchmark rates and local factors. All of these pre-
ventive strategies are employed by critical care practitioners
in an attempt to achieve zero CR-BSIs in intensive care units
(ICUs) [2,10].
Antimicrobial-impregnated (minocycline/rifampin) and
antiseptic-coated (chlorhexidine–silver sulfadiazine; Chx-SS)
CVCs have been studied extensively. Two meta-analyses
of randomized trials have established that antimicrobial/
antiseptic-coated CVCs reduce the incidence of microbial
colonization and CR-BSI, but the methodologic quality of the
studies generally was poor, putting the conclusions in doubt
[11]. The minocycline/rifampin CVCs were associated with
CR-BSI reduction, but Chx-SS CVCs were not. Furthermore,
these studies were not done in settings where infection-
prevention bundles of care were established as routine prac-
tice. The investigators concluded that coated CVCs may be
useful if the incidence of CR-BSI is above institutional goals
despite full implementation of infection prevention interven-
tions [12].
However, few studies address the efficacy of antiseptic-
coated CVCs in ICUs with low CR-BSI rates. Schuerer et al.
evaluated whether the use of Chx-SS CVCs would decrease
the CR-BSI rate in a surgical ICU (SICU) with an already low
rate. They found no statistically significant decrease in CR-BSI
rates from before implementation of the Chx-SS CVCs (3.3 per
1,000 catheter days) to after implementation (2.1 per 1,000
catheter days; p¼ 0.16)[13].
The routine use of Chx-SS CVCs was initiated in our SICU
as we implemented other educational and standardization
strategies to reduce CR-BSI. Once we achieved a low CR-BSI
rate, we began using uncoated Std CVCs instead of Chx-SS
CVCs and examined the impact of this unit-wide practice
change.
Patients and Methods
Setting
The University of Michigan 20-bed SICU admits all non-
cardiothoracic critically ill surgical patients. The SICU oper-
ates as a collaborative model in which a dedicated unit team
works closely with the admitting surgical team to facilitate
communication and coordinate all aspects of care. To mini-
mize duplication and optimize efficiency, only the SICU team
enters orders. Physician staffing includes an attending surgi-
cal or anesthesiology intensivist and an in-house resident
team that consists of a surgical or anesthesiology critical care
fellow and resident staff assigned exclusively to the SICU.
Patients
All patients admitted to the SICU were evaluated for BSIs.
Only patients identified as having a BSI who underwent
placement of a CVC by the SICU team in the internal jugular,
subclavian, or femoral position were included in the analysis.
Design
We used an interrupted time-series (quasi-experimental)
design to examine the outcomes of interest. In 2000, our
infection control team initiated the routine use of antiseptic-
coated triple-lumen CVCs (Chx-SS, first generation with
external coating [ARROWguard Blue], transitioned to second-
generation coated internally and externally [ARROWguard
Blue PLUS ; Arrow International, Inc, Reading PA]) in our
adult ICUs as we implemented other educational and stan-
dardization strategies aimed at CR-BSI reduction (hand hygiene
and antisepsis, dedicated catheter cart use, standardized
placement, chlorhexidine skin preparation, maximum sterile
barriers) (Fig. 1). Placement, use, and care for CVCs were stan-
dardized by hospital policy (see below). Empowerment of any
member of the patient care team to stop line placement in the
event of contamination or failure of protocol adherence was
enforced. Education and twice-daily evaluation of CVC removal
was performed during SICU team rounds starting in 2005.
The rate of catheter-associated (CA)-BSI decreased steadily
until 2006, during which our rate was 0.9 per 1,000 CVC days
and the rate of CR-BSI was 0 per 1,000 CVC days. In No-
vember 2007, the SICU team implemented use of standard
non-coated triple-lumen CVCs (same manufacturer) and
tracked our CA-BSI and CR-BSI rates over the following year.
All preventive efforts previously implemented regarding CA-
BSI prevention were continued. Although we did not track
compliance with hospital infection control policies, staff ed-
ucation and routine monitoring of hand washing were con-
tinued throughout the study period.
Standardization of CVC placement and care
Placement and maintenance of CVCs is standardized by
the University Hospitals and Health Centers Infection Con-
trol Committee Policy: VI-58 Central Lines: Temporary Central
and Arterial Vascular Access Catheters, Long-Term Central
Catheters: Tunneled and Ports, and Peripherally Placed
Central Catheters (PICC) [14]. The hospital policy for Use and
Maintenance of CVC Catheters was followed, which includes
washing hands before and after replacing, accessing, or re-
pairing the catheter, and before and after palpating or dress-
ing the catheter site; and use of clean gloves to remove old
dressings and either clean or sterile gloves when placing a
fresh, sterile dressing; or using an aseptic ‘‘no-touch’’ tech-
nique to apply a sterile dressing to the catheter site. The in-
sertion site is evaluated every 24 h, with every dressing
change, and when the patient complains of discomfort at the
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site. The catheter site was cleansed during dressing changes
with a 2% chlorhexidine–70% isopropyl alcohol-based prep-
aration (70% isopropyl alcohol or iodophor solution if there
was a patient allergy). Catheter sites were kept clean with a
sterile, dry, gauze dressing taped in a manner to resist mois-
ture; alternatively, a highly permeable transparent dressing
was employed.
Dressing changes also are regulated by hospital policy. Gauze
dressings or any dressing constructed with gauze or other
opaque materials were changed at least every three days or
whenever they become wet, loose, or soiled or when inspection
of the site was necessary. Highly permeable transparent dress-
ings were changed at least every seven days and as necessary.
Catheter manipulations were kept to a minimum; when
necessary, they were performed using strict aseptic technique.
A needleless access system with a pierced injection port and
blunt cannula or locking blunt cannula was used to maintain a
closed system. Access ports were changed every seven days.
A Luer-lok-type attachment was used for extension tubing.
All stopcocks were fitted with a pierced injection needleless
port at the time of set-up. Access points were disinfected with
alcohol just before entry. Blood draws through the CVCs were
kept to a minimum; when required, blood specimens were
obtained using aseptic technique and clean gloves and the
tubing, stopcock, IV port, and the access port attached to the
stopcock was flushed clean of any remaining blood after
the specimen was removed. The use of stopcocks was kept to a
minimum, and a fresh, sterile cap was used after each entry.
Stopcocks were flushed clean after blood drawing.
The SICU also adheres to University policies for changing
the intravenous tubing and attached components (secondary
tubing, extension tubing, stopcocks, locking blunt cannu-
lae, pierced injection ports/caps used on stopcocks, T-
connectors). These were changed according to the following
guidelines: Tubing for fluids, medications, hemodynamic
pressure monitoring, and parenteral nutrition without lipids
was changed every 96 h; tubing for lipids and continuous
blood products was changed at least every 24 h; and tubing
and components used for propofol administration were
changed at least every 12 h.
The SICU policy is not to remove or replace CVCs inserted
outside the unit routinely if they were placed with aseptic
technique. If CVCs are placed in an emergency situation or
under non-sterile conditions, they are removed immediately.
It is our policy never to replace CVCs over a guidewire unless
it is impossible to place a new CVC elsewhere. The internal
jugular site is preferred for CVC placement in the SICU, with
real-time ultrasound guidance to avoid technical complica-
tions and to avoid subclavian vein stenosis in patients with
advanced renal disease.
Data collection
Differentiation between CA-BSI and CR-BSI was first made
in 2005, mandating catheter tip cultures and peripheral blood
cultures in all SICU patients when CVCs were removed. A
CA-BSI was defined as a positive blood culture in a patient
with a CVC in place and no other apparent source of infection;
i.e., the CVC is assumed to be the cause of the BSI. A CR-BSI
was defined as a positive blood culture in a patient with a
CVC in place, isolation of the same organism from a semi-
quantitative or quantitative culture of a catheter segment and
from the blood of a patient with symptoms of BSI, and no
other apparent source of infection; i.e., the catheter is con-
firmed to be the cause of the BSI. Cultures from CVCs were
performed by the central microbiology laboratory using the
roll plate method, in which the cut end of the CVC catheter is
rolled across an agar plate and the numbers of colony-forming
units are counted after an incubation period [15]. Blood
stream infections were monitored by the University infection
control team, and the data were evaluated monthly by the
faculty, staff, and administration at the SICU quality assur-
ance meeting.
Statistics
We used an unpaired t-test to compare the Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) III score,
Acute Physiology Score (APS), and age differences in the
SCIU from the year before intervention with those of the post-
intervention period. A 22 contingency table was analyzed
FIG. 1. Surgical intensive care unit blood-stream infection rate, 2000–2008.
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using the w2 test with Yates correction to compare total BSI,
CA-BSI, and CR-BSI rates from the pre-intervention period
with those of the post-intervention period.
Results
Patients
The number of SICU admissions annually ranged from
1,340 to 1,491. The services admitting patients to the SICU
included Transplant, Non-Trauma Emergency, Trauma,
General Surgery, Surgical Oncology, Urology, Obstetrics/
Gynecology, Orthopedics, Otolaryngology, Vascular Surgery,
Interventional Radiology, Thoracic Surgery, and Surgical
Critical Care. Disease acuity, assessed by the admission
APACHE III score [16], increased from 52.5 in the pre-
intervention period (historical 58.2 in 2004) to 55.6 in the post-
intervention period (p¼ 0.0010; 95% confidence interval [CI]
1.29-5.13). Similarly, the mean APS [16] increased from 42.3 to
45.3 (p¼ 0.0009; 95% CI 1.22-4.74) during the same time. The
mean patient age remained the same at 57 years. There were
no differences in any other demographics or critical care
characteristics of the SICU patients during the time periods
examined (Table 1).
Catheter-associated and catheter-related blood
stream infections
The total number of CVC days during the pre-intervention
period (November 2006–October 2007) when Chx-SS-coated
triple-lumen CVCs were used exclusively was 5,580. The
mean number of catheter-days per patient was 5.79 in the pre-
intervention period and 5.87 in the post-intervention period.
The total number of CA-BSIs was three, a rate of 0.5 per 1,000
catheter-days. The total number of CR-BSIs during the pre-
intervention period was one, a CR-BSI rate of 0.2 per 1,000
catheter-days (Table 2).
The total number of CVC days during the post-intervention
period (November 2007–October 2008) when Std non-coated
triple-lumen CVCs were in use was 5,244. The total number
of CA-BSIs was four, a rate of 0.8 per 1,000 catheter-days.
The total number of CR-BSIs during the time period was
zero (Tables 2 and 3).
Causative pathogens
No difference in the causative microbial pathogens for CA-
BSI or CR-BSI was noted between the pre-intervention and
post-intervention periods (Table 3). Note that most of these
Table 2. Catheter-Associated and Catheter-Related Blood Stream Infection Rates in the Surgical
Intensive Care Unit over Time
Month/year
Catheter
type
Catheter
days
Total
BSI
Total
BSI ratea CA-BSI
CA-BSI
rate CR-BSI
CR-BSI
rate
Total
2001 Chx-SS 3,543 11 3.1 N/A N/A N/A N/A
2002 Chx-SS 3,824 26 6.8 N/A N/A N/A N/A
2003 Chx-SS 3,713 22 5.9 N/A N/A N/A N/A
2004 Chx-SS 5,385 9 1.6 N/A N/A N/A N/A
2005 Chx-SS 5,645 10 1.8 N/A N/A N/A N/A
2006 Chx-SS 5,799 5 0.9 5 0.9 0 0
2007 Chx-SS 5,395 5 0.9 4 0.7 1 0.2
11/06–10/07 (pre-intervention) Chx-SS 5,580 4 0.7 3 0.5 1 0.2
11/07–10/08 (post-intervention) Std 5,244 4 0.8 4 0.8 0 0
BSI¼ blood stream infection; CA¼ catheter-associated; CR¼ catheter-related; Chx-SS¼ chlorhexidine–silver sulfadiazine central venous
catheter; N/A¼not available; Std¼ standard catheter.
aRate¼ central venous catheter infections per 1,000 catheter-days.
Table 1. Patient Demographics and Critical Care Characteristics
Pre-intervention Post-intervention
No. of patients in surgical ICU 1,305 1,227
Mean patient age (years) (range) 56.8 (13–103) 56.7 (13–94)
Percent of patients aged 65 years 32.1 33.3
Mean APACHE III, ICU day 1 (range) 52.4 (4–188) 55.6 (7–214)
Mean Acute Physiology Score, ICU day 1 (range) 42.4 (4–188) 45.3 (7–198)
No. of patients on mechanical ventilation, ICU day 1 548 528
Admission therapy level (%)
Active treatment 851 (62.9) 811 (63.6)
High-risk monitor 119 (8.8) 155 (12.2)
Low risk monitor 377 (27.8) 301 (23.6)
Mean length of stay (days)
ICU 4.6 4.9
Hospital 13.9 18.2
Mean ventilator days 3.9 4.2
APACHE¼Acute Physiology and Chronic Health Evaluation score; ICU¼ intensive care unit.
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CA-BSIs were not confirmed as CR-BSIs, and the microbial
pathogens identified probably were not the causative patho-
gens in the CR infections.
Relation of catheter location to infection
Catheter-associated BSIs were commonly identified in
CVCs positioned in the internal jugular or femoral vein (Table
3). Subclavian CVC placement is not often performed in our
SICU because the use of real-time ultrasound guidance is
employed regularly for safety concerns.
Discussion
It has been estimated that CVCs account for approximately
90% of all blood stream infections [17,18], and more than five
million CVCs are inserted per year in the U.S. [19,20]. Anti-
microbial/antiseptic-coated and -impregnated catheters have
been designed in an attempt to reduce CR-BSI. Multiple meta-
analyses have concluded that coated CVCs are associated
with reduction in the rates of BSI, but these studies were
performed in the era when CR-BSI rates were high [20–24].
A number of studies have documented that implementa-
tion of an education program and standardization of CVC
placement in addition to full application of the CDC guide-
lines for prevention of CA-BSI is associated with a signifi-
cant reduction in CA-BSI, without the use of antimicrobial/
antiseptic-coated CVCs [25–27]. An important single-
institution study documented that the ‘‘recipe’’ for zero CR-
BSI included: (1) Standardized education of staff; (2) stan-
dardized placement of CVC; (3) having a CVC cart with all
necessary supplies; (4) daily inquiry regarding discontinua-
tion of CVC; (5) catheter-insertion checklist for assurance of
aseptic technique; and (6) empowering the team to halt the
procedure if aseptic technique rules are violated [28]. A sim-
ilar intervention was implemented state-wide in Michigan
(108 ICUs; 375,757 catheter days) without the use of antimi-
crobial/antiseptic-coated CVCs, and a significant reduction in
mean CA-BSI, from 7.7 to 1.4/1,000 catheter-days, was
documented, representing an overall 66% reduction [29].
After years of an aggressive education program, im-
plementation of the CDC guidelines, and use of Chx-SS-
coated CVCs, we reduced the incidence of CA-BSI in the SICU
to very low rates. We next examined whether Chx-SS CVCs
were an essential component of our CR-BSI infection pre-
vention efforts. By replacing the Chx-SS CVCs with non-
coated Std CVCs, we introduced a single change in our
CR-BSI infection prevention efforts that did not result in an
increase in either CA-BSI or CR-BSI. Our findings are similar
to those of Schuerer et al., who demonstrated that use of Chx-
SS-coated catheters in a SICU with an already low CA-BSI rate
failed to reduce the rate further [13].
We continue to use uncoated Std CVCs exclusively in the
SICU. Importantly, neither the CA-BSI nor the CR-BSI rate in the
SICU changed substantially over the following five months (CA-
BSI total one [0.5 per 1,000 catheter-days]; CR-BSI total zero.)
Catheter-associated BSI has been proposed to be and is
accepted as a ‘‘never’’ event; however, this is difficult to
achieve. Despite maximum multidisciplinary efforts to reduce
CA-BSI in a single ICU as a controlled environment, a per-
sistent zero rate of CA-BSI was not achievable.
The interrupted time-series (quasi-experimental) design
used to examine the impact of this intervention (use of un-
coated Std CVCs) in the SICU does have several limitations.
Most notably, it was conducted in a single SICU in a single
tertiary-care institution with all the inherent biases, and is
potentially subject to influence by changes in patient popu-
lations, ICU practices and policies, and other unrecognized
temporal biases. We did not collect data on the CVCs that
were not associated with BSI and therefore cannot make any
comments on the location, indwelling time, or specific patient
characteristics associated with CVCs not linked to BSI. Ad-
ditionally, in the SICU, CVCs are likely to be placed in a
specific subset of critically ill patients. The types of patients
and the reason for CVC placement were not tracked during
this study.
Despite these limitations, the findings of this analysis sup-
port the conclusion that aggressive education programs and
adherence to best-practice guidelines are powerful tools in the
prevention of CA-BSI and CR-BSI. In ICUs where exceptionally
low CA-BSI rates already have been achieved, the universal
use of Chx-SS-coated catheters does not yield any additional
reduction. Given the cost of $50.00 to $100.00 more for a Chx-SS
than an Std catheter, use of Std CVCs in ICUs with a low CR-
BSI rate carries potential cost savings.
Table 3. Organisms Cultured from Catheter-Associated and Catheter-Related Blood Stream Infections,
Central Venous Catheter (CVC) Position, and Days from Catheter Insertion to Infection
CA-BSI or CR-BSI Organism Vein used Days from CVC insertion to BSI
Pre-intervention (11/06–10/07)
CA-BSI Bacteroides spp. Right internal jugular 6
CA-BSI VSE Left internal jugular 20
CA-BSI Candida parapsilosis Right femoral 15
CR-BSI VRE Right femoral 10
Post-intervention (11/07–10/08)
CA-BSI VRE Right internal jugular 4
CA-BSI VSE Left femoral 26
CA-BSI Serratia spp. Left femoral 4
CA-BSI Enterobacter spp. Left internal jugular 8
Post-evaluation (11/08–4/09)
CA-BSI VRE Left subclavian 6
CA¼ catheter-associated; CR¼ catheter- related; BSI¼ blood stream infection; CVC¼ central venous line; VSE¼ vancomycin-sensitive
Enterococcus; VRE¼vancomycin-resistant Enterococcus.
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Conclusion
Elimination of the universal use of Chx-SS-coated CVCs in
an SICU with a low number of CR-BSIs did not increase the
rate of such infections. This study documents the greater
importance of adherence to standardization of the processes
of care related to CVC placement and care than of catheter
design in reducing CR-BSI.
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